Teacher Retirement System of Texas Increases Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Teacher Retirement System of Texas lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 19.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 25,412 shares of the biotechnology company’s stock after purchasing an additional 4,076 shares during the period. Teacher Retirement System of Texas’ holdings in Sarepta Therapeutics were worth $3,090,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Commerce Bank lifted its stake in shares of Sarepta Therapeutics by 15.7% in the 3rd quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock valued at $252,000 after purchasing an additional 274 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Sarepta Therapeutics by 1.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 611,749 shares of the biotechnology company’s stock valued at $76,401,000 after buying an additional 6,992 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in Sarepta Therapeutics by 13.8% during the third quarter. Daiwa Securities Group Inc. now owns 3,929 shares of the biotechnology company’s stock worth $490,000 after buying an additional 475 shares during the period. Fisher Asset Management LLC increased its position in shares of Sarepta Therapeutics by 1.3% in the third quarter. Fisher Asset Management LLC now owns 18,155 shares of the biotechnology company’s stock worth $2,267,000 after acquiring an additional 239 shares in the last quarter. Finally, Qsemble Capital Management LP purchased a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $311,000. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $73.61 on Wednesday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $7.14 billion, a price-to-earnings ratio of 58.89 and a beta of 0.79. Sarepta Therapeutics, Inc. has a twelve month low of $72.17 and a twelve month high of $173.25. The business has a 50 day simple moving average of $105.44 and a 200-day simple moving average of $117.08.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This trade represents a 8.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SRPT. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research report on Wednesday, March 19th. Scotiabank lowered their target price on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research note on Thursday, March 20th. Royal Bank of Canada reduced their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $167.41.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.